EuroPCR 25th annual meeting of the European Association of Percutaneous Cardiovascular Interventions (EAPCI) Paris 20-23 May 2014
Europcr2014 1.5
Jun 19, 2015
Europcr2014 1.5
Welcome message from author
This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
Transcript
EuroPCR25th annual meeting of the European Association of Percutaneous Cardiovascular Interventions (EAPCI)
Paris20-23 May 2014
EuroPCR 2014Paris
20-23 May 2014
Extracorporeal membrane oxygenation (ECMO) in interventional cardiology
Commentary:
Professor Andrew BoyleJohn Hunter Hospital, Newcastle
Date of preparation May 2014 │BRI001132
Disclaimer
• AstraZeneca abides by the Medicines Australia Code of Conduct (Edition 17) and AstraZeneca Global Policies, and as such will not engage in the promotion of unregistered products or unapproved indications.
• These highlights have been suggested by a group of cardiologists who attended EuroPCR 2014, compiled by an external medical writer and sponsored by AstraZeneca.
• AstraZeneca has obtained permission from EuroPCR, to utilise the selected content for educational purposes.
• Statements of fact and opinions expressed are those of the speakers individually and, unless expressly stated to the contrary, are not the opinion or position of AstraZeneca. AstraZeneca does not endorse or approve, and assumes no responsibility for, the content, accuracy, or completeness of the information presented. Presentations are intended for educational purposes only and do not replace independent professional judgement.
• Please refer to the appropriate approved Product Information before prescribing any agents mentioned in these highlights.
AstraZeneca Pty Ltd, Alma Road, North Ryde 2113 ABN: 54 009 682 311
EuroPCR 2014Paris
20-23 May 2014
EuroPCR 2014Paris
20-23 May 2014
Outcomes of cardiogenic shock remain very poor
EuroPCR 2014Paris
20-23 May 2014
EuroPCR 2014Paris
20-23 May 2014
EuroPCR 2014Paris
20-23 May 2014
Benefits of ECMO
EuroPCR 2014Paris
20-23 May 2014
EuroPCR 2014Paris
20-23 May 2014
EuroPCR 2014Paris
20-23 May 2014
EuroPCR 2014Paris
20-23 May 2014
EuroPCR 2014Paris
20-23 May 2014
ECLS = extracorporeal life support
EuroPCR 2014Paris
20-23 May 2014
EuroPCR 2014Paris
20-23 May 2014
EuroPCR 2014Paris
20-23 May 2014
ECLS implementation after in-hospital arrest
EuroPCR 2014Paris
20-23 May 2014
ECLS implementation in hospital after OHCA
EuroPCR 2014Paris
20-23 May 2014
ECLS implementation pre-hospital after OHCA
EuroPCR 2014Paris
20-23 May 2014
EuroPCR 2014Paris
20-23 May 2014
EuroPCR 2014Paris
20-23 May 2014
Similar program commenced in Prague
EuroPCR 2014Paris
20-23 May 2014
• ECMO is under-used as a resuscitation strategy in the cath lab, where it has the potential to save lives
• A cultural shift is required to take advantage of the potential, for example to resuscitate a patient with hypoxia from pulmonary haemorrhage following anticoagulation or pulmonary oedema who otherwise would have a high probability of survival, as well as for patients in cardiogenic shock.
• ECMO is not an especially complex strategy in the hospital environment.
• Pilot studies of on-site ECMO for OHCA have shown it is feasible but requires a very high degree of organisation to ensure it can be implemented rapidly while there is still some hope of successful resuscitation.
Commentary: Professor Andrew Boyle
Related Documents
